May 16, 2022 — Today, the XR Association (XRA) endorsed H.R.7051/S.3791, the bicameral, bipartisan Access to Prescription Digital Therapeutics Act of 2022, which would extend Medicare coverage for prescription digital therapeutics. The Act is sponsored by Reps. Mike Thompson (CA-05) and David McKinley (WV-01) and Sens. Jeanne Shaheen (D-NH) and Shelly Moore Capito (R-WV).
Although still emerging, XR technologies (virtual, augmented, and mixed reality) are already enhancing the delivery of healthcare and improving patient outcomes. XR technologies have shown immense potential in behavioral medicine supporting patients with post-traumatic stress, autism, attention deficit hyperactivity disorder, substance abuse, and depression. If enacted, this legislation would expand patient access to these cutting-edge treatments.
“XRA’s member companies are working to leverage cutting edge digital technologies to improve patient outcomes,” said Liz Hyman, CEO of XRA. “We’re proud to advocate for policies that anticipate and mitigate challenges in the responsible development and deployment of XR technology.”